MGX
Metagenomi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.10
−2.65%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.12
From 52W high−67.16%
Volume124383.00
Market cap$41.55M
P/E (TTM)—
P/S (TTM)3.1x
Div yield—
Key dataSep 18, 2026
Open
$1.12
From 52W high
−67.16%
Volume
124383.00
Market cap
$41.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
33.3
MomentumView details →
1D Return
−2.65%
YTD Return
−31.17%
SummaryUpdated Jun 1, 2026
Metagenomi, Inc. (NASDAQ:MGX) is a gene editing biotechnology company founded in 2016 and headquartered in Emeryville, California. The company went public in 2006 and focuses on developing therapeutic treatments using advanced genome editing technologies derived from metagenomics research. Metagenomi has established strategic partnerships with major pharmaceutical companies including Moderna, Affini-T Therapeutics, and Ionis Pharmaceuticals to advance its gene editing platform for various therapeutic applications.
Similar companies
Latest newsMore news →
Metagenomi Therapeutics reported a Q2 2026 loss of $0.73 per share, missing the Zacks Consensus Estimate of a $0.63 loss and wider than the year-ago loss of $0.54 per share.41d agoBrian C. Thomas, Ph.D. resigned as a member of the Board of Metagenomi Therapeutics, Inc., effective June 9, 2026.103d ago